Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mazdutide · 2 trials · 3 indications
Least squares means were calculated using an MMRM model for post-baseline measures: Variable = Baseline\*Time + Strata\*Time + Treatment\*Time, where Treatment and Strata are factors. Variance-Covariance structure (Percent Change from Baseline) = Unstructured. Strata is defined by joint levels of Sex and Baseline BMI (\<=30, \>30 kg/m\^2).
| Arm | Type | Description |
|---|---|---|
| Mazdutide | EXPERIMENTAL | Mazdutide administered subcutaneously (SC). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| 3/6 Milligrams (mg) Mazdutide | EXPERIMENTAL | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (3 or 6 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-31, then 6 mg from Weeks 32-48. |
| 10 mg Mazdutide | EXPERIMENTAL | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (10 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 8 mg from Weeks 12-15, and then 10 mg from Weeks 16-48. |
| 16 mg Mazdutide | EXPERIMENTAL | Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (16 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-7, 6 mg from Weeks 8-11, 9 mg from Weeks 12-15, 12 mg from Weeks 16-19, and then16 mg from Weeks 20-48. |
| Name | Type | Description |
|---|---|---|
| Mazdutide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Exclusion Criteria: * Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the la...
Mazdutide is an investigational small molecule being studied for the treatment of obesity, overweight, and alcohol use disorder. It is being developed by Eli Lilly and Company (LLY). The drug is currently in Phase 2 clinical development and is not yet approved by the FDA.
Mazdutide is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its effects on obesity, overweight, and alcohol use disorder, but the precise mechanism of action is not publicly detailed.
Mazdutide is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is currently in Phase 2 clinical trials for obesity, overweight, and alcohol use disorder.
Mazdutide is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been completed, one in obesity or overweight and one in alcohol use disorder.
Mazdutide has been studied in two completed Phase 2 trials. NCT06124807 evaluated the drug in 179 adults with obesity or overweight in the United States. NCT06817356 evaluated the drug in 308 adults with alcohol use disorder in the United States.
Yes, Mazdutide is also known as LY3305677. The clinical trial NCT06124807, which studied the drug in participants with obesity or overweight, refers to the compound as LY3305677. Both names refer to the same investigational drug.